SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Summit Therapeutics Inc (SMMT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum in technical indicators, has mixed analyst ratings, and faces near-term uncertainty in its clinical trials. While the company has significant cash reserves and ongoing trials, the lack of immediate catalysts and pre-market price decline suggest holding off for now.
The MACD is positive but contracting, RSI is neutral at 54.65, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 15.682 with resistance at 16.53 and support at 14.834. Pre-market price is down 0.76%, showing weak sentiment.
The company is participating in three investor conferences in March 2026, which could enhance visibility. The HARMONi-3 squamous cohort data in Q2 has the potential to revitalize the stock and lead to FDA engagement. Analysts see opportunities in multiple tumor types.
The stock has a high chance of declining in the next week and month based on historical patterns.
In Q4 2025, the company reported no revenue growth, net income of -$219.17 million (up 258.11% YoY), and an EPS of -$0.29 (up 262.50% YoY). While improvements are evident, the company remains unprofitable.
Mixed ratings: Citi maintains a Buy rating with a $40 target, citing potential catalysts in Q2. H.C. Wainwright lowered the price target to $30 from $40, citing uncertainty. Barclays upgraded the stock to Equal Weight with a $18 target, highlighting meaningful updates in 2026.
